Skip to main content
SpringerLink
Log in

Tolerization to Brain and Vascular Antigens: Targeting Autoimmunity After Acute Brain Injuries and Preventing Stroke

  • Chapter
  • First Online:
Immunological Mechanisms and Therapies in Brain Injuries and Stroke

Part of the book series: Springer Series in Translational Stroke Research ((SSTSR,volume 6))

  • 1230 Accesses

Abstract

The immune response can contribute to the risk of stroke as well as to brain injury following stroke. Directed modulation of the immune response to attenuate risk or injury is thus a potential therapeutic strategy for treating stroke. Inducing a population of antigen-specific regulatory T cells is one such strategy and can be used to locally modulate the immune response to the organs in which the antigen is present, thereby limiting potential side effects. This chapter addresses the use of mucosal tolerance to both prevent and treat ischemic stroke.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jander S, Kraemer M, Schroeter M, Witte OW, Stoll G (1995) Lymphocytic infiltration and expression of intercellular adhesion molecule-1 in photochemically induced ischemia of the rat cortex. J Cereb Blood Flow Metab 15(1):42–51

    Article  PubMed  CAS  Google Scholar 

  2. Schroeter M, Jander S, Witte OW, Stoll G (1994) Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion. J Neuroimmunol 55(2):195–203

    Article  PubMed  CAS  Google Scholar 

  3. Braun JS, Jander S, Schroeter M, Witte OW, Stoll G (1996) Spatiotemporal relationship of apoptotic cell death to lymphomonocytic infiltration in photochemically induced focal ischemia of the rat cerebral cortex. Acta Neuropathol (Berl) 92(3):255–63

    Article  CAS  Google Scholar 

  4. Campanella M, Sciorati C, Tarozzo G, Beltramo M (2002) Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke 33(2):586–92

    Article  PubMed  Google Scholar 

  5. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ (2000) Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 31(11):2670–7

    Article  PubMed  CAS  Google Scholar 

  6. Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR (2006) Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 37(10):2508–13

    Article  PubMed  CAS  Google Scholar 

  7. van Zwam M, Huizinga R, Melief MJ, Wierenga-Wolf AF, van Meurs M, Voerman JS et al (2009) Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med 87(3):273–86

    Article  PubMed  Google Scholar 

  8. Planas AM, Gomez-Choco M, Urra X, Gorina R, Caballero M, Chamorro A (2012) Brain-derived antigens in lymphoid tissue of patients with acute stroke. J Immunol 188(5):2156–63

    Article  PubMed  CAS  Google Scholar 

  9. Youngchaiyud U, Coates AS, Whittingham S, Mackay IR (1974) Cellular-immune response to myelin protein: absence in multiple sclerosis and presence in cerebrovascular accidents. Aust N Z J Med 4(6):535–8

    Article  PubMed  CAS  Google Scholar 

  10. Kallen B, Nilsson O, Thelin C (1977) Effect of encephalitogenic protein on migration in agarose of leukoytes from patients with multiple sclerosis. A longitudinal study of patients with relapsing multiple sclerosis or with cerebral infarction. Acta Neurol Scand 55(1):47–56

    Article  Google Scholar 

  11. Rocklin RE, Sheremata WA, Feldman RG, Kies MW, David JR (1971) The Guillain-Barre syndrome and multiple sclerosis. In vitro cellular responses to nervous-tissue antigens. N Engl J Med 284(15):803–8

    Article  PubMed  CAS  Google Scholar 

  12. Prass K, Meisel C, Hoflich C, Braun J, Halle E, Wolf T et al (2003) Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 198(5):725–36

    Article  PubMed  CAS  Google Scholar 

  13. Wong CH, Jenne CN, Lee WY, Leger C, Kubes P (2011) Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science 334(6052):101–5

    Article  PubMed  CAS  Google Scholar 

  14. Becker K (2012) Autoimmune responses to brain following stroke. Transl Stroke Res

    Google Scholar 

  15. Becker KJ, Kindrick DL, Lester MP, Shea C, Ye ZC (2005) Sensitization to brain antigens after stroke is augmented by lipopolysaccharide. J Cereb Blood Flow Metab 25(12):1634–44

    Article  PubMed  CAS  Google Scholar 

  16. Zierath D, Thullbery M, Hadwin J, Gee JM, Savos A, Kalil A et al (2010) CNS immune responses following experimental stroke. Neurocrit Care 12(2):274–84

    Article  PubMed  Google Scholar 

  17. Becker KJ, Kalil AJ, Tanzi P, Zierath DK, Savos AV, Gee JM et al (2011) Autoimmune responses to the brain after stroke are associated with worse outcome. Stroke 42:2763–9

    Article  PubMed  CAS  Google Scholar 

  18. Gee JM, Kalil A, Thullbery M, Becker KJ (2008) Induction of immunologic tolerance to myelin basic protein prevents central nervous system autoimmunity and improves outcome after stroke. Stroke 39(5):1575–82

    Article  PubMed  Google Scholar 

  19. Gee JM, Zierath D, Hadwin J, Savos A, Kalil A, Thullbery M et al (2009) Long term immunologic consequences of experimental stroke and mucosal tolerance. Exp Transl Stroke Med 1:3

    Article  PubMed  Google Scholar 

  20. Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N et al (2010) Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol 87(3):385–95

    Article  PubMed  CAS  Google Scholar 

  21. Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D (2011) Post-stroke infection: a systematic review and meta-analysis. BMC Neurol 11:110

    Article  PubMed  Google Scholar 

  22. Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ et al (1998) Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. Stroke 29(2):447–53

    Article  PubMed  CAS  Google Scholar 

  23. Aslanyan S, Weir CJ, Diener HC, Kaste M, Lees KR (2004) Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol 11(1):49–53

    Article  PubMed  CAS  Google Scholar 

  24. Katzan IL, Cebul RD, Husak SH, Dawson NV, Baker DW (2003) The effect of pneumonia on mortality among patients hospitalized for acute stroke. Neurology 60(4):620–5

    Article  PubMed  CAS  Google Scholar 

  25. Minnerup J, Wersching H, Brokinkel B, Dziewas R, Heuschmann PU, Nabavi DG et al (2010) The impact of lesion location and lesion size on poststroke infection frequency. J Neurol Neurosurg Psychiatr 81(2):198–202

    Article  PubMed  Google Scholar 

  26. Hug A, Dalpke A, Wieczorek N, Giese T, Lorenz A, Auffarth G et al (2009) Infarct volume is a major determiner of post-stroke immune cell function and susceptibility to infection. Stroke 40(10):3226–32

    Article  PubMed  Google Scholar 

  27. Tanzi P, Cain K, Kalil A, Zierath D, Savos A, Gee JM et al (2011) Post-stroke infection: a role for IL-1ra? Neurocrit Care 14(2):244–52

    Article  PubMed  CAS  Google Scholar 

  28. Hong KS, Kang DW, Koo JS, Yu KH, Han MK, Cho YJ et al (2008) Impact of neurological and medical complications on 3-month outcomes in acute ischaemic stroke. Eur J Neurol 15(12):1324–31

    Article  PubMed  Google Scholar 

  29. Vermeij FH, Scholte op Reimer WJ, de Man P, van Oostenbrugge RJ, Franke CL, de Jong G (2009) Stroke-associated infection is an independent risk factor for poor outcome after acute ischemic stroke: data from the Netherlands Stroke Survey. Cerebrovasc Dis 27(5):465–71

    Article  PubMed  Google Scholar 

  30. Oppenheim JJ, Tewary P, de la Rosa G, Yang D (2007) Alarmins initiate host defense. Adv Exp Med Biol 601:185–94

    Article  PubMed  Google Scholar 

  31. Yang D, de la Rosa G, Tewary P, Oppenheim JJ (2009) Alarmins link neutrophils and dendritic cells. Trends Immunol 30(11):531–7

    Article  PubMed  CAS  Google Scholar 

  32. Bianchi ME, Manfredi AA (2007) High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 220:35–46

    Article  PubMed  CAS  Google Scholar 

  33. Meisel C, Prass K, Braun J, Victorov I, Wolf T, Megow D et al (2004) Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke. Stroke 35(1):2–6

    Article  PubMed  CAS  Google Scholar 

  34. Chamorro A, Horcajada JP, Obach V, Vargas M, Revilla M, Torres F et al (2005) The early systemic prophylaxis of infection after stroke study: a randomized clinical trial. Stroke 36(7):1495–500

    Article  PubMed  CAS  Google Scholar 

  35. Harms H, Prass K, Meisel C, Klehmet J, Rogge W, Drenckhahn C et al (2008) Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS One 3(5):e2158

    Article  PubMed  Google Scholar 

  36. Schwarz S, Al-Shajlawi F, Sick C, Meairs S, Hennerici MG (2008) Effects of prophylactic antibiotic therapy with mezlocillin plus sulbactam on the incidence and height of fever after severe acute ischemic stroke: the Mannheim infection in stroke study (MISS). Stroke 39(4):1220–7

    Article  PubMed  CAS  Google Scholar 

  37. Savos AV, Gee JM, Zierath D, Becker KJ (2011) alpha-MSH: A potential neuroprotective and immunomodulatory agent for the treatment of stroke. J Cereb Blood Flow Metab 31(2):606–13

    Article  PubMed  CAS  Google Scholar 

  38. Miller A, Lider O, Weiner HL (1991) Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 174(4):791–8

    Article  PubMed  CAS  Google Scholar 

  39. Becker KJ, McCarron RM, Ruetzler C, Laban O, Sternberg E, Flanders KC et al (1997) Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc Natl Acad Sci U S A 94(20):10873–8

    Article  PubMed  CAS  Google Scholar 

  40. Becker K, Kindrick D, McCarron R, Hallenbeck J, Winn R (2003) Adoptive transfer of myelin basic protein-tolerized splenocytes to naive animals reduces infarct size: a role for lymphocytes in ischemic brain injury? Stroke 34(7):1809–15

    Article  PubMed  CAS  Google Scholar 

  41. Frenkel D, Huang Z, Maron R, Koldzic DN, Moskowitz MA, Weiner HL (2005) Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci 233(1–2):125–32

    Article  PubMed  CAS  Google Scholar 

  42. Spera PA, Ellison JA, Feuerstein GZ, Barone FC (1998) IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 251(3):189–92

    Article  PubMed  CAS  Google Scholar 

  43. Grilli M, Barbieri I, Basudev H, Brusa R, Casati C, Lozza G et al (2000) Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage. Eur J Neurosci 12(7):2265–72

    Article  PubMed  CAS  Google Scholar 

  44. Zhou Z, Peng X, Insolera R, Fink DJ, Mata M (2009) Interleukin-10 provides direct trophic support to neurons. J Neurochem 110(5):1617–27

    Article  PubMed  CAS  Google Scholar 

  45. Justicia C, Perez-Asensio FJ, Burguete MC, Salom JB, Planas AM (2001) Administration of transforming growth factor-alpha reduces infarct volume after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 21(9):1097–104

    Article  PubMed  CAS  Google Scholar 

  46. Henrich-Noack P, Prehn JH, Krieglstein J (1996) TGF-beta 1 protects hippocampal neurons against degeneration caused by transient global ischemia. Dose-response relationship and potential neuroprotective mechanisms. Stroke 27(9):1609–14, discussion 15

    Article  PubMed  CAS  Google Scholar 

  47. Ma M, Ma Y, Yi X, Guo R, Zhu W, Fan X et al (2008) Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. BMC Neurosci 9:117

    Article  PubMed  Google Scholar 

  48. Hallenbeck JM, Dutka AJ, Kochanek PM, Siren A, Pezeshkpour GH, Feuerstein G (1988) Stroke risk factors prepare rat brainstem tissues for modified local Shwartzman reaction. Stroke 19(7):863–9

    Article  PubMed  CAS  Google Scholar 

  49. Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2(8):675–80

    Article  PubMed  CAS  Google Scholar 

  50. Thomas L (1983) The youngest science: notes of a medicine-watcher. Viking, New York

    Google Scholar 

  51. Liu Y, Liu T, McCarron RM, Spatz M, Feuerstein G, Hallenbeck JM et al (1996) Evidence for activation of endothelium and monocytes in hypertensive rats. Am J Physiol 270(6 Pt 2):H2125–31

    PubMed  CAS  Google Scholar 

  52. Rosenberg RD, Aird WC (1999) Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 340(20):1555–64

    Article  PubMed  CAS  Google Scholar 

  53. Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B (1989) Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 243(4895):1160–5

    Article  PubMed  CAS  Google Scholar 

  54. Takeda H, Spatz M, Ruetzler C, McCarron R, Becker K, Hallenbeck J (2002) Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke 33(9):2156–63

    Article  PubMed  CAS  Google Scholar 

  55. Chen Y, Ruetzler C, Pandipati S, Spatz M, McCarron RM, Becker K et al (2003) Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci U S A 100(25):15107–12

    Article  PubMed  CAS  Google Scholar 

  56. Hallenbeck J (2010) How inflammation modulates central nervous system vessel activation and provides targets for intervention–a personal perspective. Ann N Y Acad Sci 1207:1–7

    Article  PubMed  Google Scholar 

  57. Ishibashi S, Maric D, Mou Y, Ohtani R, Ruetzler C, Hallenbeck JM (2009) Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in spontaneously hypertensive rats. J Cereb Blood Flow Metab 29(3):606–20

    Article  PubMed  CAS  Google Scholar 

  58. Vila J, Isaacs JD, Anderson AE (2009) Regulatory T cells and autoimmunity. Curr Opin Hematol 16(4):274–9

    Article  PubMed  CAS  Google Scholar 

  59. Lee YK, Mukasa R, Hatton RD, Weaver CT (2009) Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 21(3):274–80

    Article  PubMed  CAS  Google Scholar 

  60. Xiao BG, Link H (1997) Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol 85(2):119–28

    Article  PubMed  CAS  Google Scholar 

  61. Blanas E, Carbone FR, Allison J, Miller JF, Heath WR (1996) Induction of autoimmune diabetes by oral administration of autoantigen. Science 274(5293):1707–9

    Article  PubMed  CAS  Google Scholar 

  62. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linington C et al (1996) Late complications of immune deviation therapy in a nonhuman primate. Science 274(5295):2054–7

    Article  PubMed  CAS  Google Scholar 

  63. Hafler DA, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Fukaura H (1997) Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann N Y Acad Sci 835:120–31

    Article  PubMed  CAS  Google Scholar 

  64. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA (1996) Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 98(1):70–7

    Article  PubMed  CAS  Google Scholar 

  65. Wei W, Zhang LL, Xu JH, Xiao F, Bao CD, Ni LQ et al (2009) A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis. Arthritis Res Ther 11(6):R180

    Article  PubMed  Google Scholar 

  66. Choy EH, Scott DL, Kingsley GH, Thomas S, Murphy AG, Staines N et al (2001) Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum 44(9):1993–7

    Article  PubMed  CAS  Google Scholar 

  67. Barnett ML, Kremer JM, St Clair EW, Clegg DO, Furst D, Weisman M et al (1998) Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 41(2):290–7

    Article  PubMed  CAS  Google Scholar 

  68. Fourlanos S, Perry C, Gellert SA, Martinuzzi E, Mallone R, Butler J et al (2011) Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 60(4):1237–45

    Article  PubMed  CAS  Google Scholar 

  69. Nussenblatt R (2004) Orally and nasally induced tolerance studies in ocular inflammatory disease: guidance for future interventions. Ann N Y Acad Sci 1029:278–85

    Article  PubMed  CAS  Google Scholar 

  70. Kraus TA, Mayer L (2005) Oral tolerance and inflammatory bowel disease. Curr Opin Gastroenterol 21(6):692–6

    Article  PubMed  Google Scholar 

  71. Margalit M, Israeli E, Shibolet O, Zigmond E, Klein A, Hemed N et al (2006) A double-blind clinical trial for treatment of Crohn’s disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am J Gastroenterol 101(3):561–8

    Article  PubMed  CAS  Google Scholar 

  72. Ilan Y (2004) Oral immune regulation toward disease-associated antigens: results of phase I clinical trials in Crohn’s disease and chronic hepatitis. Ann N Y Acad Sci 1029:286–98

    Article  PubMed  CAS  Google Scholar 

  73. Hallenbeck J, Del Zoppo G, Jacobs T, Hakim A, Goldman S, Utz U et al (2006) Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary. Stroke 37(12):3035–42

    Article  PubMed  Google Scholar 

  74. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018–28

    Article  PubMed  CAS  Google Scholar 

  75. Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353(4):369–74

    Article  PubMed  CAS  Google Scholar 

  76. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353(4):375–81

    Article  PubMed  CAS  Google Scholar 

  77. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9(4):438–46

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology and Neurological Surgery, University of Washington School of Medicine, Seattle, WA, USA

    Kyra J. Becker

  2. Stroke Branch, NINDS, NIH, Bethesda, MD, USA

    John Hallenbeck

Authors
  1. Kyra J. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Hallenbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyra J. Becker .

Editor information

Editors and Affiliations

  1. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

    Jun Chen

  2. Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

    Xiaoming Hu

  3. Molecular Microbiology & Immunology, Oregon Health & Sciences University, Portland, Oregon, USA

    Mary Stenzel-Poore

  4. Loma Linda University, Loma Linda, California, USA

    John H. Zhang

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Becker, K.J., Hallenbeck, J. (2014). Tolerization to Brain and Vascular Antigens: Targeting Autoimmunity After Acute Brain Injuries and Preventing Stroke. In: Chen, J., Hu, X., Stenzel-Poore, M., Zhang, J. (eds) Immunological Mechanisms and Therapies in Brain Injuries and Stroke. Springer Series in Translational Stroke Research, vol 6. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8915-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8915-3_16

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8914-6

  • Online ISBN: 978-1-4614-8915-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation